The Design and Rationale of a Phase 2b, Randomized, Double-Blinded, and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B in Older Adults with Frailty
Authors:
- K.N. RamdasKRK.N. Ramdas
- J.G. RuizJRJ.G. Ruiz
- J. WalstonJWJ. Walston
- H. AraiHAH. Arai
- E. VolpiEVE. Volpi
- A.B. NewmanANA.B. Newman
- C. WangCWC. Wang
- B. HitchinsonBHB. Hitchinson
- L. McClain-MossLML. McClain-Moss
- L. DiazLDL. Diaz
- G.A. GreenGGG.A. Green
Open Access
- 1 April 2022
- journal article
- research article
- Published by Elsevier in The Journal of Frailty & Aging
- Vol. 11 (2) , 214-223
Abstract
Frailty in older adults is a rapidly growing unmet medical need. It is an aging-related syndrome characterized by physical decline leading to higher risk of adverse health outcomes. To evaluate the efficacy of Lomecel-B, an allogeneic medicinal signaling cell (MSC) formulation, in older adults with frailty. This multicenter, randomized, parallel-arm, double-blinded, and placebo-controlled phase 2b trial is designed to evaluate dose-range effects of Lomecel-B for frailty on physical functioning, patient-reported outcomes (PROs), frailty status, and biomarkers. Eight enrolling clinical research centers, including the Miami Veterans Affairs Medical Center. Target enrollment is 150 subjects aged 70-85 years of any race, ethnicity, or gender. Enrollment criteria include a Clinical Frailty Score of 5 ("mild") or 6 ("moderate"), a 6MWT of 200-400 m, and serum tumor necrosis factor-alpha (TNF-α) ≥2.5 pg/mL. A single intravenous infusion of Lomecel-B (25, 50, 100, or 200 million cells) or placebo (N=30/arm). Patients are followed for 365 days for safety, and the efficacy assessments performed at 90, 180, and 270 days. The primary endpoint is change in 6MWT in the Lomecel-B-treated arms versus placebo at 180 days post-infusion. Secondary and exploratory endpoints include change in: 6MWT and other physical function measures at all time points; PROs; frailty status; cognitive status; and an inflammatory biomarkers panel. A pre-specified sub-study examines vascular/endothelial biomarkers. Safety is evaluated throughout the trial. The trial is conducted under a Food and Drug Administration Investigational New Drug (IND), with Institutional Review Board approval, and monitoring by an NIH-appointed independent Data Safety Monitoring Board. This clinical trial investigates the use of a regenerative medicine strategy for frailty in older adults. The results will further the understanding of the potential for Lomecel-B in the geriatric condition of frailty.Keywords
This publication has 64 references indexed in Scilit:
- Frailty prevalence and slow walking speed in persons age 65 and older: implications for primary careBMC Family Practice, 2013
- The minimal clinically important difference of six-minute walk in Asian older adultsBMC Geriatrics, 2013
- Association of frailty with survival: A systematic literature reviewAgeing Research Reviews, 2013
- Frailty and Sexual Health in Older European MenThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2012
- Frailty Defined by Deficit Accumulation and Geriatric Medicine Defined by FrailtyClinics in Geriatric Medicine, 2011
- The Frailty Syndrome: Definition and Natural HistoryClinics in Geriatric Medicine, 2011
- The Biology of Aging and FrailtyClinics in Geriatric Medicine, 2011
- Frailty, inflammation and the elderlyBiogerontology, 2010
- The 6‐Minute Walk Is Associated With Frailty and Predicts Mortality in Older Adults With Heart FailureCongestive Heart Failure, 2010
- Middle-aged and mobility-limited prevalence of disability and symptom attributions in a national surveyJournal of General Internal Medicine, 2006